Axcella Health Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Axcella Health Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11309
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Axcella Health Inc (Axcella), formerly Pronutria Biosciences Inc is a developer of disease-specific amino acid profiles. The company’s lead clinical-stage candidates AXA are based on cell-specific sets of amino acids that regulate multiple biological pathways. Its amino acid therapies helps in treating orphan diseases in muscle, neurological, metabolic and liver settings, which include myotonic dystrophy, intractable epilepsy syndromes, pediatric nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, sarcopenia and other disease populations. Axcella conducts human signal seeking and confirming studies to understand the impact of various AXA candidates on human liver biology. The company uses a proprietary platform to identify the amino acid profile associated with a medical condition and de-risk the clinical development process. Axcella is headquartered in Cambridge, Massachusetts, the US.

Axcella Health Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Axcella Health Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Axcella Health Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Pronutria Raises USD39 Million in Series C Financing 10
Pronutria Raises USD28.3 Million in Venture Financing 11
Pronutria Raises US$12.3 Million In Series B Financing 12
Axcella Health (Pronutria Biosciences) Secures USD12.25 Million in Series B Funding Round 13
Pronutria Raises US$10.8 Million In Series A Financing 14
Partnerships 15
KineMed Enters into R&D Agreement with Pronutria Biosciences 15
Equity Offering 16
Pronutria Biosciences Raises USD42.5 Million in Equity Investment 16
Axcella Health Inc – Key Competitors 17
Axcella Health Inc – Key Employees 18
Axcella Health Inc – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Corporate Communications 20
Oct 22, 2018: Axcella appoints Stephen Mitchener, PharmD, to senior vice president, chief business officer 20
Jun 27, 2018: Axcella Welcomes William D. Baird, and Cristina M. Rondinone to Board of Directors 21
May 31, 2018: Axcella Health Names Bill Hinshaw as President and Chief Executive Officer 23
Jan 03, 2018: Axcella Announces Appointment of David Epstein, Former CEO of Novartis Pharmaceuticals, as Chairman of its Board of Directors 24
Sep 14, 2017: Axcella Appoints Manu Chakravarthy, M.D., Ph.D., as Chief Medical Officer 25
Jun 14, 2017: Axcella Appoints Tony Tramontin, Ph.D., as Senior Vice President, Chief Scientific Officer 26
May 11, 2017: Axcella Announces the Appointment of Ivana Magovcevic-Liebisch, Ph.D., J.D., as Executive Vice President, Chief Strategy and Corporate Development Officer 27
Jan 03, 2017: Axcella Augments Leadership Team with the Appointment of Three Key Hires 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Axcella Health Inc, Pharmaceuticals & Healthcare, Key Facts 2
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Axcella Health Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Axcella Health Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Pronutria Raises USD39 Million in Series C Financing 10
Pronutria Raises USD28.3 Million in Venture Financing 11
Pronutria Raises US$12.3 Million In Series B Financing 12
Axcella Health (Pronutria Biosciences) Secures USD12.25 Million in Series B Funding Round 13
Pronutria Raises US$10.8 Million In Series A Financing 14
KineMed Enters into R&D Agreement with Pronutria Biosciences 15
Pronutria Biosciences Raises USD42.5 Million in Equity Investment 16
Axcella Health Inc, Key Competitors 17
Axcella Health Inc, Key Employees 18

List of Figures
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Axcella Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Axcella Health Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Urenco Ltd:企業の戦略・SWOT・財務分析
    Urenco Ltd - Strategy, SWOT and Corporate Finance Report Summary Urenco Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Yamaha Motor Co Ltd (7272):企業の財務・戦略的SWOT分析
    Yamaha Motor Co Ltd (7272) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Virgin Media Inc.:企業の戦略的SWOT分析
    Virgin Media Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • MTU Aero Engines Holdings AG (MTX):企業の財務・戦略的SWOT分析
    MTU Aero Engines Holdings AG (MTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • ViroMed Co Ltd (084990):製薬・医療:M&Aディール及び事業提携情報
    Summary ViroMed Co Ltd (ViroMed), formerly ViroMedica Pacific Inc is a biotechnology company that discovers and develops biopharmaceuticals and phytotherapeutics for human diseases. The company provides therapeutic drugs such as therapeutic angiogenesis for cardiovascular diseases, therapeutic cance …
  • Credit Agricole CIB SA:企業の戦略的SWOT分析
    Credit Agricole CIB SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Nissin Electric Co Ltd (6641):企業の財務・戦略的SWOT分析
    Nissin Electric Co Ltd (6641) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • BP Plc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    BP Plc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary BP Plc (BP) is an integrated oil and gas company. Its upstream activities include exploration, development and production of oil and natural gas, field development and production; and midstream operations inc …
  • China Merchants Securities Co Ltd (600999):企業の財務・戦略的SWOT分析
    China Merchants Securities Co Ltd (600999) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Chiyoda Corporation (6366)-石油・ガス分野:企業M&A・提携分析
    Summary Chiyoda Corporation (Chiyoda) is an engineering services provider that offers various services along with its subsidiaries. Its offerings include project management, program management, feasibility studies, front end engineering design works, engineering, procurement, construction, commissio …
  • Zenotech Laboratories Ltd (532039):企業の財務・戦略的SWOT分析
    Zenotech Laboratories Ltd (532039) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Carso Infraestructura y Construccion SA De CV:企業の戦略・SWOT・財務情報
    Carso Infraestructura y Construccion SA De CV - Strategy, SWOT and Corporate Finance Report Summary Carso Infraestructura y Construccion SA De CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, opera …
  • Enmax Corporation:電力:M&Aディール及び事業提携情報
    Summary ENMAX Corporation (ENMAX), a subsidiary of City of Calgary, is a vertically integrated energy utility. It generates, transmits and distributes electricity; supplies natural gas; and provides value-added services. Through its subsidiaries, the company undertakes deregulated electricity genera …
  • The Depository Trust & Clearing Corp:企業の戦略的SWOT分析
    The Depository Trust & Clearing Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Verily Life Sciences LLC-医療機器分野:企業M&A・提携分析
    Summary Verily Life Sciences LLC (Verily), formerly known as Google Life Sciences LLC, a subsidiary of Alphabet Inc is a life sciences research and engineering organization which develops tools for prevention, detection, and management of diseases. The company develops tools for various projects, su …
  • Strongbridge Biopharma plc (SBBP):製薬・医療:M&Aディール及び事業提携情報
    Summary Strongbridge Biopharma Plc (Strongbridge Biopharma), formerly Cortendo Plc is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases. The company’s marketed product KEVEYIS (dichlorphenamide) is indicated for the treatment of hypokalemic, hy …
  • Liberty Star Uranium & Metals Corp (LBSR):企業の財務・戦略的SWOT分析
    Summary Liberty Star Uranium & Metals Corp (Liberty Star), formerly Liberty Star Gold Corp is a mining and mineral exploration and development company that offers mineral resources. The company offers acquisition, exploration, operations, management, mining, production, and development of gold, copp …
  • Stem Inc:電力:M&Aディール及び事業提携情報
    Summary Stem, Inc. (Stem) is a provider of energy storage solutions and software to businesses for managing energy costs. It leverages big data, predictive analytics, cloud computing, and advanced energy storage to reduce peak electrical usage, lower electric bills, and eliminate the need for new ge …
  • Yokogawa Electric Corporation:企業の戦略・SWOT・財務分析
    Yokogawa Electric Corporation - Strategy, SWOT and Corporate Finance Report Summary Yokogawa Electric Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Agros Development Company “Proodos” Public Ltd:企業の戦略・SWOT・財務情報
    Agros Development Company “Proodos” Public Ltd - Strategy, SWOT and Corporate Finance Report Summary Agros Development Company “Proodos” Public Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆